Martin Dreyling

from Wikipedia, the free encyclopedia

Martin Heinz Dreyling (* 1961 in Wuppertal ) is a German hematologist and oncologist and professor at the Ludwig Maximilians University in Munich .

Life

Dreyling studied human medicine at the Heinrich Heine University in Düsseldorf , the Justus Liebig University in Gießen , the Eberhard Karls University in Tübingen and the Julius Maximilians University in Würzburg . After completing the medical state examination , he obtained his license to practice medicine in 1987 and began his internship at the University Hospital Bonn in 1988 . In 1990 he received his doctorate on the subject of "Investigations into the validity of indirect clinical parameters of myocardial oxygen consumption in normal and pathological ventricular function". In the same year he moved to Münster , where he worked first at the Clemenshospital and then at the university clinic . He then did a research stay in the field of hematology and oncology at the University of Chicago in the USA from 1992 to 1995 . He then returned to Germany and completed his internship at the University Hospital Göttingen and the Ludwig Maximilians University Hospital in Munich , where he passed his specialist examination in 1998. In 2001 he completed his habilitation on the subject of “Molecular genetic and functional characterization of the tumor suppressor region of the chromosomal band 9p21 in hematological cell lines and lymphomas and leukemia” and was appointed senior physician a year later. In October 2007 he was offered the W2 professorship in "Immunotherapy and Molecular Biology" at the Ludwig Maximilians University Clinic in Munich.

Act

Dreyling's clinical research focus is on the development and application of new therapeutic approaches for patients with haematological or oncological diseases, including in particular malignant lymphomas such as chronic lymphocytic leukemia or mantle cell lymphoma . In his experimental research, Dreyling deals with the characterization of molecular genetic changes in the context of the development of malignant lymphomas. In terms of translational medicine , the implementation of experimental results in clinical applications is also planned. Dreyling is a member of various medical societies and sits on the advisory board of the German Society for Hematology and Medical Oncology (DGHO).

Web links

Individual evidence

  1. ↑ MünchnerUni Magazin: Newly appointed: Prof. Dr. Martin Heinz Dreyling (2013 edition, number 4; page 28), accessed on January 5, 2016.
  2. ↑ a b Clinic of the University of Munich: Career of Prof. Dr. M. Dreyling , accessed January 5, 2016.
  3. ↑ German National Library : Studies on the validity of indirect clinical parameters of myocardial oxygen consumption in normal and pathological ventricular function , accessed on January 5, 2016.
  4. ^ German Cancer Society: CV of Prof. Dr. med. Martin Heinz Dreyling , accessed January 5, 2016.
  5. ^ Hospital of the University of Munich: Prof. Dr. M. Dreyling , accessed January 5, 2016.
  6. ↑ German Society for Hematology and Medical Oncology: The Advisory Board of the DGHO , accessed on January 5, 2016.
personal data
SURNAME Dreyling, Martin
ALTERNATIVE NAMES Dreyling, Martin Heinz (full name)
BRIEF DESCRIPTION German hematologist and oncologist and professor
DATE OF BIRTH 1961
PLACE OF BIRTH Wuppertal